Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Stomach Neoplasms 3Neoplasm Metastasis 3Recurrence 2Nasopharyngeal Carcinoma 2Melanoma 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Prostatic Neoplasms 1Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma 1Lung Neoplasms 1Locally Advanced Colorectal Cancer 1Hodgkin Disease 1HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma 1Gastric Adenocarcinoma 1Colorectal Cancer Metastatic 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer 1Advanced Solid Tumor 1Advanced Malignant Tumors 1Advanced Gastric Cancer 1

Interventions

Cyclophosphamide 153Dexamethasone 141Rituximab 85fludarabine 79Lenalidomide 72Cytarabine 70Bortezomib 64fludarabine phosphate 63Gemcitabine 62venetoclax 54Etoposide 53pomalidomide 52pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × SHR-1701 × Clear all
NCT05896046 2023-06-15

SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Chinese PLA General Hospital

Phase 1/2 Recruiting
100 enrolled
Lymphoid

Hodgkin Disease, Recurrence

NCT05503888 2022-08-17

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1/2 Not yet recruiting
160 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡